Mee Kyoung Kim1, Kyungdo Han1, Eun Sil Koh1, Hun-Sung Kim1, Hyuk-Sang Kwon1, Yong-Moon Park1, Kun-Ho Yoon1, Seung-Hwan Lee2. 1. From the Division of Endocrinology and Metabolism, Department of Internal Medicine, Yeouido St. Mary's Hospital (M.K.K., H.-S. Kwon), Department of Medical Statistics (K.H.), Division of Nephrology, Department of Internal Medicine, Yeouido St. Mary's Hospital (E.S.K.), Division of Endocrinology and Metabolism, Department of Internal Medicine, Seoul St. Mary's Hospital (H.-S. Kim, K.-H.Y., S.-H.L.), and Department of Medical Informatics (H.-S. Kim, K.-H.Y.), College of Medicine, The Catholic University of Korea, Seoul; and Epidemiology Branch, National Institute of Environmental Health Sciences, National Institutes of Health, Research Triangle Park, NC (Y.-M.P.). 2. From the Division of Endocrinology and Metabolism, Department of Internal Medicine, Yeouido St. Mary's Hospital (M.K.K., H.-S. Kwon), Department of Medical Statistics (K.H.), Division of Nephrology, Department of Internal Medicine, Yeouido St. Mary's Hospital (E.S.K.), Division of Endocrinology and Metabolism, Department of Internal Medicine, Seoul St. Mary's Hospital (H.-S. Kim, K.-H.Y., S.-H.L.), and Department of Medical Informatics (H.-S. Kim, K.-H.Y.), College of Medicine, The Catholic University of Korea, Seoul; and Epidemiology Branch, National Institute of Environmental Health Sciences, National Institutes of Health, Research Triangle Park, NC (Y.-M.P.). hwanx2@catholic.ac.kr.
Abstract
OBJECTIVE: Recent data suggest that visit-to-visit variability of cholesterol is associated with cardiovascular events. We evaluated the role of lipid variability as a determinant of end-stage renal disease (ESRD). APPROACH AND RESULTS: Using nationally representative data from the Korean National Health Insurance System, 8 493 277 subjects who were free of ESRD and who underwent ≥3 health examinations during 2005 to 2010 were followed to the end of 2015. Total cholesterol (TC) variability was measured using the coefficient of variation, SD, and the variability independent of the mean. The primary outcome was the development of ESRD, defined as a combination of the relevant disease code and the initiation of renal replacement therapy. There were 11 247 cases of ESRD during a median follow-up of 6.1 years. There was a graded association between a higher TC variability and incident ESRD. In the multivariable adjusted model, the hazard ratios and 95% confidence intervals comparing the highest versus lowest quartiles of coefficient of variation of TC were 2.66 (95% confidence interval, 2.52-2.82). The results were consistent when the variability of TC was modeled using SD and variability independent of the mean and were independent of preexisting chronic kidney disease. CONCLUSIONS: Increasing TC variability was associated with an increasing incidence of ESRD.
OBJECTIVE: Recent data suggest that visit-to-visit variability of cholesterol is associated with cardiovascular events. We evaluated the role of lipid variability as a determinant of end-stage renal disease (ESRD). APPROACH AND RESULTS: Using nationally representative data from the Korean National Health Insurance System, 8 493 277 subjects who were free of ESRD and who underwent ≥3 health examinations during 2005 to 2010 were followed to the end of 2015. Total cholesterol (TC) variability was measured using the coefficient of variation, SD, and the variability independent of the mean. The primary outcome was the development of ESRD, defined as a combination of the relevant disease code and the initiation of renal replacement therapy. There were 11 247 cases of ESRD during a median follow-up of 6.1 years. There was a graded association between a higher TC variability and incident ESRD. In the multivariable adjusted model, the hazard ratios and 95% confidence intervals comparing the highest versus lowest quartiles of coefficient of variation of TC were 2.66 (95% confidence interval, 2.52-2.82). The results were consistent when the variability of TC was modeled using SD and variability independent of the mean and were independent of preexisting chronic kidney disease. CONCLUSIONS: Increasing TC variability was associated with an increasing incidence of ESRD.
Authors: Daniel J Brotman; Lori D Bash; Rehan Qayyum; Deidra Crews; Eric A Whitsel; Brad C Astor; Josef Coresh Journal: J Am Soc Nephrol Date: 2010-07-08 Impact factor: 10.121
Authors: Chi-yuan Hsu; Charles E McCulloch; Carlos Iribarren; Jeanne Darbinian; Alan S Go Journal: Ann Intern Med Date: 2006-01-03 Impact factor: 25.391
Authors: Areef Ishani; Greg A Grandits; Richard H Grimm; Kenneth H Svendsen; Allan J Collins; Ronald J Prineas; James D Neaton Journal: J Am Soc Nephrol Date: 2006-04-12 Impact factor: 10.121
Authors: Josef Coresh; Elizabeth Selvin; Lesley A Stevens; Jane Manzi; John W Kusek; Paul Eggers; Frederick Van Lente; Andrew S Levey Journal: JAMA Date: 2007-11-07 Impact factor: 56.272
Authors: James Shepherd; John J P Kastelein; Vera Bittner; Prakash Deedwania; Andrei Breazna; Stephen Dobson; Daniel J Wilson; Andrea Zuckerman; Nanette K Wenger Journal: Clin J Am Soc Nephrol Date: 2007-10-17 Impact factor: 8.237
Authors: Dae Hyun Kim; Lewis A Lipsitz; Luigi Ferrucci; Ravi Varadhan; Jack M Guralnik; Michelle C Carlson; Lee A Fleisher; Linda P Fried; Paulo H M Chaves Journal: J Am Geriatr Soc Date: 2006-11 Impact factor: 5.562
Authors: Da Young Lee; Kyungdo Han; Ji Hee Yu; Sanghyun Park; Jee-In Heo; Ji A Seo; Nam Hoon Kim; Hye Jin Yoo; Sin Gon Kim; Seon Mee Kim; Kyung Mook Choi; Sei Hyun Baik; Yong Gyu Park; Nan Hee Kim Journal: Sci Rep Date: 2020-07-15 Impact factor: 4.379
Authors: Eric Y F Wan; Esther Y T Yu; Weng Y Chin; Jessica K Barrett; Anna H Y Mok; Christie S T Lau; Yuan Wang; Ian C K Wong; Esther W Y Chan; Cindy L K Lam Journal: Diabetes Obes Metab Date: 2020-06-24 Impact factor: 6.577
Authors: Eun Sil Koh; Kyung Do Han; Mee Kyoung Kim; Eun Sook Kim; Min-Kyung Lee; Ga Eun Nam; Hyuk-Sang Kwon Journal: Korean J Intern Med Date: 2021-05-13 Impact factor: 2.884